openPR Logo
Press release

OTC: VWAGY / OTC: VLKAF / OTC: VWAPY Shareholder Notice: Update in Lawsuit against Volkswagen AG

03-11-2020 03:17 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit is pending for certain investors in Volkswagen AG (OTC: VWAGY) (OTC: VWAPY) shares.

A lawsuit is pending for certain investors in Volkswagen AG (OTC: VWAGY) (OTC: VWAPY) shares.

The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Volkswagen AG (OTC: VWAGY) (OTC: VWAPY) shares.

Investors, who purchased shares of Volkswagen AG (OTC: VWAGY) (OTC: VLKAF) (OTC: VWAPY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On September 25, 2015, a lawsuit was filed against Volkswagen AG (alleged securities laws violations. The plaintiff claimed that the defendants misled investors by failing to disclose that the Company had utilized a "defeat device" in certain of its diesel cars that allowed such cars to temporarily reduce emissions during testing, while achieving higher performance and fuel economy, as well as discharging dramatically higher emissions, when testing was not being conducted. The use of this device allowed Volkswagen to market its diesel vehicles to environmentally conscious consumers, increasing its sale of diesel cars in the United States and abroad and, as a result, its profitability. As a result of defendants' scheme and false and misleading statements and omissions, Volkswagen's ordinary and preferred ADRs traded at artificially inflated prices, reaching highs of $54.82 and $56.55 per ADR, respectively, on December 30, 2013.

The Company pled guilty to criminal charges, paid a $2.8 billion criminal fine, a $2.7 billion fine for environmental mitigation, another $2 billion for clean-emissions infrastructure, while total costs associated to rectifying the emissions issue have exceeded $18 billion.

Those who purchased shares of Volkswagen AG (OTC: VWAGY) (OTC: VLKAF) (OTC: VWAPY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release OTC: VWAGY / OTC: VLKAF / OTC: VWAPY Shareholder Notice: Update in Lawsuit against Volkswagen AG here

News-ID: 1962580 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors who lost money with shares of Altimmune, Inc. (NASDAQ: ALT) over possible Violations of Securities Laws
Investigation announced for Investors who lost money with shares of Altimmune, I …
An investigation was announced for investors of Altimmune, Inc. (NASDAQ: ALT) shares over potential securities laws violations by Altimmune, Inc. Investors who purchased shares of Altimmune, Inc. (NASDAQ: ALT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Altimmune, Inc. (NASDAQ: ALT) concerning whether a series
Investigation announced for Long-Term Investors in shares of Medical Properties Trust, Inc. (NYSE: MPW) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of Medical Properties …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Medical Properties Trust, Inc.. Investors who are current long term investors in Medical Properties Trust, Inc. (NYSE: MPW) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: MPW stocks follows a lawsuit filed
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: DBI) over possible Violations of Securities Laws
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: D …
An investigation was announced for investors of Designer Brands Inc. (NYSE: DBI) shares over potential securities laws violations by Designer Brands Inc. Investors who purchased shares of Designer Brands Inc. (NYSE: DBI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Designer Brands Inc. (NYSE: DBI)
Investigation announced for Investors in shares of Pyxis Oncology, Inc. (NASDAQ: PYXS) over potential Wrongdoing
Investigation announced for Investors in shares of Pyxis Oncology, Inc. (NASDAQ: …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Pyxis Oncology, Inc. Investors who purchased shares of Pyxis Oncology, Inc. (NASDAQ: PYXS) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Pyxis Oncology, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Cambridge,

All 5 Releases


More Releases for OTC:

Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF). Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to
Investigation for Long-Term Investors in shares of Volkswagen AG (OTC: VWAGY / O …
An investigation on behalf of current long-term investors in shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) was announced over potential breaches of fiduciary duties by certain officers and directors at Volkswagen AG. Investors who purchased shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) and currently hold any of those Volkswagen AG shares have certain options and should contact the Shareholders Foundation at
OTC Analgesics Market OTC analgesics market is projected to register a steady ex …
About OTC Analgesics Market The global OTC analgesics market is projected to register an above-average CAGR during 2017 to 2022. Global sales of OTC analgesics is estimated to account for nearly US$ 25,000 Mn revenues by 2022-end. Get Sample copy of this Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=75 The trend of using off-label drugs that are affordable and unapproved, but effective in treating diseases, has been witnessing an upsurge over the past few years.
03-14-2018 | Health & Medicine
Fact.MR
OTC Analgesics Market Report 2017-22: Pharmacy to Remain the Most Lucrative OTC …
A fresh study, covering “OTC Analgesics Market Forecast, Trend Analysis & Competition Tracking – Global Review 2017 to 2022” has been broadcasted to wide online repository of Fact MR, which presents deep focus on the healthcare market. This smart study contains precise data that offers a clear insight about market current scenario and future projections for the benefit of readers. Moreover, the study enclosed significant data which tends to make
The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects
ReportsWeb.com has announced the addition of the “Global OTC Drugs Market Research Report 2017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. GBI Research's latest report, "The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects" discusses trends in the over-the-counter (OTC) pharmaceuticals market and the commercial prospects for switching drugs from prescription-only to OTC status. The report assesses current
The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects
ReportsWeb.com has announced the addition of the “Global OTC Drugs Market Research Report 2017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. GBI Research's latest report, "The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects" discusses trends in the over-the-counter (OTC) pharmaceuticals market and the commercial prospects for switching drugs from prescription-only to OTC status. The report assesses current